CervoMed Inc
CRVO
View Detailed Chart
5.310USD
+0.710+15.43%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
49.13MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+15.43%
5 Days
+3.11%
1 Month
-29.62%
6 Months
-45.20%
Year to Date
-32.78%
1 Year
+138.12%
View Detailed Chart
TradingKey Stock Score of CervoMed Inc
Currency: USD Updated: 2026-02-06Key Insights
CervoMed Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 140 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 22.43.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CervoMed Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
CervoMed Inc Highlights
StrengthsRisks
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.74M.
Fairly Valued
The company’s latest PE is -1.83, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 354.95K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.81.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
22.429
Target Price
+387.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CervoMed Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CervoMed Inc Info
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Ticker SymbolCRVO
CompanyCervoMed Inc
CEOAlam (John J)
Websitehttps://cervomed.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68126.510
-1843.620 (-2.63%)
282.580
+22.390 (+8.61%)
2014.700
-37.030 (-1.80%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
